vs
Side-by-side financial comparison of RAMBUS INC (RMBS) and TransMedics Group, Inc. (TMDX). Click either name above to swap in a different company.
RAMBUS INC is the larger business by last-quarter revenue ($180.2M vs $160.8M, roughly 1.1× TransMedics Group, Inc.). TransMedics Group, Inc. runs the higher net margin — 65.6% vs 33.2%, a 32.3% gap on every dollar of revenue. On growth, TransMedics Group, Inc. posted the faster year-over-year revenue change (32.2% vs 8.1%). Over the past eight quarters, TransMedics Group, Inc.'s revenue compounded faster (28.8% CAGR vs 16.8%).
Rambus Inc. is an American technology company that designs, develops and licenses chip interface technologies and architectures that are used in digital electronics products. The company, founded in 1990, is well known for inventing RDRAM and for its intellectual property-based litigation following the introduction of DDR-SDRAM memory.
TransMedics Group, Inc. develops and commercializes innovative medical technologies for organ transplantation. Its flagship Organ Care System keeps donor organs viable during transport, improving transplant outcomes for heart, lung, liver and kidney recipients. It serves transplant centers and organ procurement organizations across North America, Europe and Asia-Pacific.
RMBS vs TMDX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.2M | $160.8M |
| Net Profit | $59.9M | $105.4M |
| Gross Margin | 79.7% | 58.1% |
| Operating Margin | 34.3% | 13.2% |
| Net Margin | 33.2% | 65.6% |
| Revenue YoY | 8.1% | 32.2% |
| Net Profit YoY | -7.3% | 1436.9% |
| EPS (diluted) | $0.55 | $2.59 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $180.2M | — | ||
| Q4 25 | $190.2M | $160.8M | ||
| Q3 25 | $178.5M | $143.8M | ||
| Q2 25 | $172.2M | $157.4M | ||
| Q1 25 | $166.7M | $143.5M | ||
| Q4 24 | $161.1M | $121.6M | ||
| Q3 24 | $145.5M | $108.8M | ||
| Q2 24 | $132.1M | $114.3M |
| Q1 26 | $59.9M | — | ||
| Q4 25 | $63.8M | $105.4M | ||
| Q3 25 | $48.4M | $24.3M | ||
| Q2 25 | $57.9M | $34.9M | ||
| Q1 25 | $60.3M | $25.7M | ||
| Q4 24 | $62.2M | $6.9M | ||
| Q3 24 | $48.7M | $4.2M | ||
| Q2 24 | $36.1M | $12.2M |
| Q1 26 | 79.7% | — | ||
| Q4 25 | 78.9% | 58.1% | ||
| Q3 25 | 79.5% | 58.8% | ||
| Q2 25 | 79.8% | 61.4% | ||
| Q1 25 | 80.3% | 61.5% | ||
| Q4 24 | 80.4% | 59.2% | ||
| Q3 24 | 80.7% | 55.9% | ||
| Q2 24 | 79.7% | 60.6% |
| Q1 26 | 34.3% | — | ||
| Q4 25 | 37.2% | 13.2% | ||
| Q3 25 | 35.4% | 16.2% | ||
| Q2 25 | 36.6% | 23.2% | ||
| Q1 25 | 37.9% | 19.1% | ||
| Q4 24 | 35.9% | 7.1% | ||
| Q3 24 | 37.6% | 3.6% | ||
| Q2 24 | 30.5% | 10.9% |
| Q1 26 | 33.2% | — | ||
| Q4 25 | 33.6% | 65.6% | ||
| Q3 25 | 27.1% | 16.9% | ||
| Q2 25 | 33.6% | 22.2% | ||
| Q1 25 | 36.2% | 17.9% | ||
| Q4 24 | 38.6% | 5.6% | ||
| Q3 24 | 33.4% | 3.9% | ||
| Q2 24 | 27.3% | 10.7% |
| Q1 26 | $0.55 | — | ||
| Q4 25 | $0.58 | $2.59 | ||
| Q3 25 | $0.44 | $0.66 | ||
| Q2 25 | $0.53 | $0.92 | ||
| Q1 25 | $0.56 | $0.70 | ||
| Q4 24 | $0.57 | $0.19 | ||
| Q3 24 | $0.45 | $0.12 | ||
| Q2 24 | $0.33 | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $134.3M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $473.1M |
| Total Assets | $1.5B | $1.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $134.3M | — | ||
| Q4 25 | $182.8M | — | ||
| Q3 25 | $79.2M | — | ||
| Q2 25 | $87.8M | — | ||
| Q1 25 | $132.2M | — | ||
| Q4 24 | $99.8M | — | ||
| Q3 24 | $114.0M | $330.1M | ||
| Q2 24 | $124.6M | $362.8M |
| Q1 26 | — | — | ||
| Q4 25 | $1.4B | $473.1M | ||
| Q3 25 | $1.3B | $355.2M | ||
| Q2 25 | $1.2B | $318.1M | ||
| Q1 25 | $1.2B | $266.3M | ||
| Q4 24 | $1.1B | $228.6M | ||
| Q3 24 | $1.0B | $209.9M | ||
| Q2 24 | $1.0B | $189.9M |
| Q1 26 | $1.5B | — | ||
| Q4 25 | $1.5B | $1.1B | ||
| Q3 25 | $1.4B | $946.0M | ||
| Q2 25 | $1.5B | $890.5M | ||
| Q1 25 | $1.4B | $837.5M | ||
| Q4 24 | $1.3B | $804.1M | ||
| Q3 24 | $1.3B | $785.6M | ||
| Q2 24 | $1.3B | $758.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $34.5M |
| Free Cash FlowOCF − Capex | — | $19.0M |
| FCF MarginFCF / Revenue | — | 11.8% |
| Capex IntensityCapex / Revenue | — | 9.7% |
| Cash ConversionOCF / Net Profit | — | 0.33× |
| TTM Free Cash FlowTrailing 4 quarters | — | $133.6M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $99.8M | $34.5M | ||
| Q3 25 | $88.4M | $69.6M | ||
| Q2 25 | $94.4M | $91.6M | ||
| Q1 25 | $77.4M | $-2.9M | ||
| Q4 24 | $59.0M | $19.7M | ||
| Q3 24 | $62.1M | $6.9M | ||
| Q2 24 | $70.4M | $25.7M |
| Q1 26 | — | — | ||
| Q4 25 | $93.3M | $19.0M | ||
| Q3 25 | $82.5M | $61.9M | ||
| Q2 25 | $87.9M | $82.5M | ||
| Q1 25 | $69.5M | $-29.9M | ||
| Q4 24 | $52.5M | $6.1M | ||
| Q3 24 | $52.2M | $-41.3M | ||
| Q2 24 | $59.1M | $2.0M |
| Q1 26 | — | — | ||
| Q4 25 | 49.0% | 11.8% | ||
| Q3 25 | 46.2% | 43.1% | ||
| Q2 25 | 51.0% | 52.4% | ||
| Q1 25 | 41.7% | -20.8% | ||
| Q4 24 | 32.6% | 5.0% | ||
| Q3 24 | 35.9% | -38.0% | ||
| Q2 24 | 44.7% | 1.7% |
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | 9.7% | ||
| Q3 25 | 3.3% | 5.3% | ||
| Q2 25 | 3.8% | 5.8% | ||
| Q1 25 | 4.7% | 18.8% | ||
| Q4 24 | 4.0% | 11.2% | ||
| Q3 24 | 6.8% | 44.3% | ||
| Q2 24 | 8.6% | 20.8% |
| Q1 26 | — | — | ||
| Q4 25 | 1.56× | 0.33× | ||
| Q3 25 | 1.83× | 2.86× | ||
| Q2 25 | 1.63× | 2.62× | ||
| Q1 25 | 1.28× | -0.11× | ||
| Q4 24 | 0.95× | 2.87× | ||
| Q3 24 | 1.28× | 1.63× | ||
| Q2 24 | 1.95× | 2.11× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RMBS
| Product revenue | $88.0M | 49% |
| Royalties | $69.6M | 39% |
| Contract and other revenue | $22.6M | 13% |
TMDX
| Liver Product | $127.0M | 79% |
| Heart Product | $26.0M | 16% |
| Other | $5.9M | 4% |
| Lung Product | $1.9M | 1% |
